C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy
<p>Abstract</p> <p>Objective</p> <p>C-reactive protein (CRP) is considered a useful serum marker for patients with RCC. However, its clinical utility in advanced metastatic renal cell carcinoma (AM-RCC), particularly in deciding whether to perform nephrectomy at the ons...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-08-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://www.biomedcentral.com/1471-2407/12/337 |
| _version_ | 1818363119823486976 |
|---|---|
| author | Ito Hiroki Shioi Koichi Murakami Takayuki Takizawa Akitoshi Sano Futoshi Kawahara Takashi Mizuno Nobuhiko Makiyama Kazuhide Nakaigawa Noboru Kishida Takeshi Miura Takeshi Kubota Yoshinobu Yao Masahiro |
| author_facet | Ito Hiroki Shioi Koichi Murakami Takayuki Takizawa Akitoshi Sano Futoshi Kawahara Takashi Mizuno Nobuhiko Makiyama Kazuhide Nakaigawa Noboru Kishida Takeshi Miura Takeshi Kubota Yoshinobu Yao Masahiro |
| author_sort | Ito Hiroki |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Objective</p> <p>C-reactive protein (CRP) is considered a useful serum marker for patients with RCC. However, its clinical utility in advanced metastatic renal cell carcinoma (AM-RCC), particularly in deciding whether to perform nephrectomy at the onset, is not well studied.</p> <p>Patients and methods</p> <p>We retrospectively evaluated 181 patients with AM-RCC, including 18 patients underwent potentially curative surgery, 111 underwent cytoreductive nephrectomy, and 52 received medical treatment only. CRP cutoff points were determined by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier and Cox regression analyses were used for survival tests.</p> <p>Results</p> <p>ROC analysis suggested that grouping patients according to 3 CRP ranges was a rational model. Patients with highly elevated CRP (≥67.0 mg/L) presented remarkably poor prognosis despite treatment (nephrectomy or medical treatment only). Cox regression models demonstrated that risk factors of overall survival for patients who underwent nephrectomy were the CRP ranges defined in this study (≤18.0 mg/L, >18.0 and <67.0 mg/L, and ≥67.0 mg/L), ECOG PS (0, 1, and ≥2), and number of metastatic organ sites (0–1 and ≥2). The retrospective design is a limitation of this study.</p> <p>Conclusion</p> <p>Our study demonstrated that the serum CRP level is a statistically significant prognostic parameter for patients with AM-RCC. The data also indicated that pretreatment serum CRP level provides useful prognostic information that helps in deciding whether to perform initial nephrectomy for patients with AM-RCC.</p> |
| first_indexed | 2024-12-13T21:43:25Z |
| format | Article |
| id | doaj.art-92d5a4e2a04247dab65023be31a28991 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-13T21:43:25Z |
| publishDate | 2012-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-92d5a4e2a04247dab65023be31a289912022-12-21T23:30:30ZengBMCBMC Cancer1471-24072012-08-0112133710.1186/1471-2407-12-337C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomyIto HirokiShioi KoichiMurakami TakayukiTakizawa AkitoshiSano FutoshiKawahara TakashiMizuno NobuhikoMakiyama KazuhideNakaigawa NoboruKishida TakeshiMiura TakeshiKubota YoshinobuYao Masahiro<p>Abstract</p> <p>Objective</p> <p>C-reactive protein (CRP) is considered a useful serum marker for patients with RCC. However, its clinical utility in advanced metastatic renal cell carcinoma (AM-RCC), particularly in deciding whether to perform nephrectomy at the onset, is not well studied.</p> <p>Patients and methods</p> <p>We retrospectively evaluated 181 patients with AM-RCC, including 18 patients underwent potentially curative surgery, 111 underwent cytoreductive nephrectomy, and 52 received medical treatment only. CRP cutoff points were determined by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier and Cox regression analyses were used for survival tests.</p> <p>Results</p> <p>ROC analysis suggested that grouping patients according to 3 CRP ranges was a rational model. Patients with highly elevated CRP (≥67.0 mg/L) presented remarkably poor prognosis despite treatment (nephrectomy or medical treatment only). Cox regression models demonstrated that risk factors of overall survival for patients who underwent nephrectomy were the CRP ranges defined in this study (≤18.0 mg/L, >18.0 and <67.0 mg/L, and ≥67.0 mg/L), ECOG PS (0, 1, and ≥2), and number of metastatic organ sites (0–1 and ≥2). The retrospective design is a limitation of this study.</p> <p>Conclusion</p> <p>Our study demonstrated that the serum CRP level is a statistically significant prognostic parameter for patients with AM-RCC. The data also indicated that pretreatment serum CRP level provides useful prognostic information that helps in deciding whether to perform initial nephrectomy for patients with AM-RCC.</p>http://www.biomedcentral.com/1471-2407/12/337C-reactive proteinRena cell carcinomaPrognosis |
| spellingShingle | Ito Hiroki Shioi Koichi Murakami Takayuki Takizawa Akitoshi Sano Futoshi Kawahara Takashi Mizuno Nobuhiko Makiyama Kazuhide Nakaigawa Noboru Kishida Takeshi Miura Takeshi Kubota Yoshinobu Yao Masahiro C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy BMC Cancer C-reactive protein Rena cell carcinoma Prognosis |
| title | C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy |
| title_full | C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy |
| title_fullStr | C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy |
| title_full_unstemmed | C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy |
| title_short | C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy |
| title_sort | c reactive protein in patients with advanced metastatic renal cell carcinoma usefulness in identifying patients most likely to benefit from initial nephrectomy |
| topic | C-reactive protein Rena cell carcinoma Prognosis |
| url | http://www.biomedcentral.com/1471-2407/12/337 |
| work_keys_str_mv | AT itohiroki creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT shioikoichi creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT murakamitakayuki creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT takizawaakitoshi creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT sanofutoshi creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT kawaharatakashi creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT mizunonobuhiko creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT makiyamakazuhide creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT nakaigawanoboru creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT kishidatakeshi creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT miuratakeshi creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT kubotayoshinobu creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy AT yaomasahiro creactiveproteininpatientswithadvancedmetastaticrenalcellcarcinomausefulnessinidentifyingpatientsmostlikelytobenefitfrominitialnephrectomy |